The alliance will pair EVERSANA's NAVLIN platform, which provides data and information on global pricing and market access, ...

As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the ...

At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

Digital tools, powered by intuitive design, AI, and customer centricity, offer a unique opportunity to bridge the trust gap ...

Artificial intelligence startup Quibim has raised $50 million in first-round financing to support the rollout of its ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Over 6.3 million patients make up the NHS backlog for consultant-led elective care, which reached 7,573,212 in September 2024 ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...